Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Cancer Research|May 19, 2006
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysisChristina S Schuetz, Michael Bonin, Susan E Clare, et al.Breast Cancer Research : BCR|October 17, 2008
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1Hans Neubauer, Susan E Clare, Wojciech Wozny, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2017
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE StudyCarlo Genova, Mark A Socinski, Rebecca R Hozak, et al.Cancer Chemotherapy and Pharmacology|June 18, 2016
Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumorsDavid C Smith, John Powderly, James J Lee, et al.Molecular Cancer Therapeutics|March 12, 2009
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancerMarcus M Schittenhelm, Christian Kollmannsberger, Karin Oechsle, et al.Electrophoresis|April 29, 2006
Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detectionHans Neubauer, Susan E Clare, Raffael Kurek, et al.Cancer Research|November 20, 2002
Proteomics of human breast ductal carcinoma in situJulia D Wulfkuhle, Dennis C Sgroi, Henry Krutzsch, et al.Cancer Research|May 8, 2007
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brainDiane Palmieri, Julie L Bronder, Jeanne M Herring, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2010
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancerJoan H Schiller, Joachim von Pawel, Philipp Schütt, et al.Therapeutic Innovation & Regulatory Science|February 20, 2020
Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future DirectionsGreg Ball, Raffael Kurek, Barbara A Hendrickson, et al.Pageof 3